Prognostic and Therapeutic Applications of RKIP in Cancer

Prognostic and Therapeutic Applications of RKIP in Cancer

1st Edition - February 3, 2020

Write a review

  • Editors: Benjamin Bonavida, Stavroula Baritaki
  • Hardcover ISBN: 9780128196120
  • eBook ISBN: 9780128224519

Purchase options

Purchase options
DRM-free (PDF, EPub, Mobi)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students.

Key Features

  • Provides an update from experts in the field on diagnostics, prognostics and therapeutics
  • Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter
  • Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals


Cancer researchers, medical scientists, clinicians, graduate students

Table of Contents

  • 1. RKIP: General Properties in Human MalignanciesInsight on the Role of RKIP in Cancer through Key Protein Partners and Cellular Protrusions
    Francoise Schoentgen
    2. Function of BACH1 as a key target of RKIP in Breast Cancer
    Marsha Rich Rosner & Jiyoung Lee
    3. Pleiotropic Activities of RKIP in Cancer: Role in Survival, EMT, Chemo-immuno-resistance, and Autophagy
    Yuhao Wang & Benjamin Bonavida
    4. Role of RKIP in the Tumor Response to Photo-oxidative Damage
    Valentina Rapozzi & Luigi Emilio Xodo
    5. A Review of RKIP Promotion of Tumour Progression, Metastasis and Poor Outcome in Multiple Solid Tumour Types
    Sharon Glynn, Eoin Dervan, & Dibyangana Bhattacharyya
    6. Tumor hypoxic stress, cellular plasticity and RKIP
    Salem Chouaib, Stéphane Terry, Stéphanie Buart, & Abérémane Abdou
    7. RKIP in Uterine Tissues
    Pasquapina Ciarmela
    8. The Role of RAF Kinase Inhibitor Protein in Hematologic Malignancies
    Armin Zebisch
    9. RKIP Regulation and Crosstalks Regulation of RKIP Expression in Breast Cancer Cells by miRNA
    Kam Yeung, Julius Castro, Hussain N. Odeh, Christopher Figy, Miranda L. Yeung, & Robert Trumbly
    10. The Master Cellular Regulators “RKIP & GSK3β”: Their Interactions and Repercussions on Cancer
    Mira Bosso & Fahd Al-Mulla
    11. Identification of Regulatory Crosstalks between RKIP and BCRA1 Tumor Suppressors in Healthy Tissues and Cancer (Breast and Ovarian): Therapeutic Implications
    Martina Rama & Benjamin Bonavida
    12. RKIP a Master of Regulatory Pathways: Perspectives
    Khosrow Kashfi, Yongxin Zhou, & Gabrielle M. Corrente
    13. Local and Systemic Endothelial Dysfunction in Cancer: RKIP-Mimetic, Therapy of Cancer and Endothelium-Safety
    Marta Smeda, Marek Grosicki, & Stefan Chlopicki
    14. Stochastic Modeling for Investigation of Regulation of Transcription of RKIP gene
    Alexandre Ramos, Leonardo dos Reis Gama, Mauro César Cafundó Morais, & Poliana Cristina de Melo Martins
    15. Anti-cancer effect of RKIP via modulating autophagy during metastasis
    Deok Ryong Kim & Mahmoud Ahmed
    16. RKIP and Inflammation The Role of Raf Kinase Inhibitory Protein in Inflammation
    Steve Shenouda, Fahd Al-Mulla, Mira Bosso,& Rasheed Ahmad
    17. Role of RKIP in inflammatory responses
    Xiaojian Wang & Wenlong Lin
    18. RKIP: Prognostic and Therapeutic Implications RKIP in Human Diseases and its Potential as a Prognostic Indicator and Therapeutic Target
    Apostolos Zaravinos & Theodoulakis Christofi
    19. Therapeutic Targeting of SNAIL, RKIP and YY1 in Tumor Metastasis and Drug Resistance
    Nadire Özenver & Thomas Efferth
    20. Implications of RKIP protein in cancer prognosis and therapy response: a literature update
    Diana Cardoso-Carneiro, Ana Raquel-Cunha, Joana Pinheiro, Maria Gabriela-Freitas, Patrícia Fontão, Rui M. Reis, & Olga Martinho
    21. Theranostic Role of RKIP in Cancer
    Ganji Purnachandra Nagaraju, Begum Dariya, Gayathri Chalikonda, & Afroz Alam
    22. Downregulation of the Raf Kinase Inhibitory Protein (RKIP) in Clear Cell Renal Cell Carcinoma Associates with Poor Prognosis
    Damu Tang Anil Kapoor, Xiaozeng Lin, David Rodrig

Product details

  • No. of pages: 504
  • Language: English
  • Copyright: © Academic Press 2020
  • Published: February 3, 2020
  • Imprint: Academic Press
  • Hardcover ISBN: 9780128196120
  • eBook ISBN: 9780128224519

About the Editors

Benjamin Bonavida

Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.

Affiliations and Expertise

Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA

Stavroula Baritaki

Stavroula Baritaki’s, PhD, areas of expertise mainly include the understanding of the molecular mechanisms involved in tumor cell therapeutic resistance and acquisition of a metastatic phenotype. Her studies have revealed novel gene products, including Raf-1 Kinase inhibitory protein (RKIP), as members of molecular ‘circuitries and networks’ that critically affect tumor immunosurveillance, resistance to chemo/immune-therapy and early metastasis-related cell transformations, such as EMT. Followed by further studies on the epigenetic and post-translational regulation of RKIP in many cancer types, her overall findings have firstly suggested the RKIP downregulation in cancer cells as a putative gene signature of tumor chemo/immune-resistance and EMT with prognostic and therapeutic significance in an individualized basis. On this context, Dr. Baritaki has extended her research interests in identifying novel agents that through RKIP induction are able to inhibit EMT or improve either the host immunosurveillance and/or the efficacy of anti-tumor therapies, especially if they are combined with conventional immuno-stimulatory or chemotherapeutic regimens. Most of these agents are currently under clinical trials.

Affiliations and Expertise

Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece

Ratings and Reviews

Write a review

Latest reviews

(Total rating for all reviews)

  • Olga M. Mon Feb 10 2020

    One of the best books ever in the cancer biology field

    This is a wonderfulll and super complete book regarding an extremelly important protein in the cancer field , the RKIP. I completley reccomend this book.